James A Katz

Presbyopia – A Review of Current Treatment Options and Emerging Therapies

E. Donnenfeld, P. Karpecki, Mark Wuttke, 2021, Clinical ophthalmology.

Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment

Mitchell A Jackson, Jonathan D. Solomon, Terry Kim, 2017, Current opinion in ophthalmology.

Current Opinion in Current Opinion in Dysfunctional Tear Syndrome: Dry Eye Disease and Associated Tear Film Disorders -new Strategies for Diagnosis and Treatment to Obtain Ama Pra Category 1 Credit

Mitchell A Jackson, Jonathan D. Solomon, Terry Kim, 2022 .

An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite®

S. J. Lichtenstein, D. Granet, James A Katz, 2007, Clinical ophthalmology.

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

Mitchell A Jackson, J. Hovanesian, K. Nichols, 2021, Clinical ophthalmology.

Loteprednol Etabonate for the Treatment of Dry Eye Disease

P. Majmudar, James A Katz, K. Beckman, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Secretary for Quality of Care

M. Repka, D. Wallace, C. Summers, 2012 .

Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease.

James A Katz, L. Periman, E. Sarnicola, 2022, Clinical therapeutics.

KPI-121 0.25%: A New Option for the Treatment of Dry Eye Disease

P. Majmudar, James A Katz, K. Beckman, 2021, US Ophthalmic Review.